Document 0110
 DOCN  M95B0110
 TI    Efficacy of antenatal zidovudine in reducing perinatal transmission of
       human immunodeficiency virus type 1. The New York City Perinatal HIV
       Transmission Collaborative Study Group.
 DT    9511
 AU    Matheson PB; Abrams EJ; Thomas PA; Hernan MA; Thea DM; Lambert G;
       Krasinski K; Bamji M; Rogers MF; Heagarty M; Medical and Health Research
       Association of New York City, Inc.,; New York, USA.
 SO    J Infect Dis. 1995 Aug;172(2):353-8. Unique Identifier : AIDSLINE
       MED/95348531
 AB    New York City women (321) enrolled during 1986-1993 in an observational
       cohort study were analyzed retrospectively to determine the
       effectiveness of antenatal zidovudine in reducing perinatal transmission
       of human immunodeficiency virus type 1 (HIV-1) in women with various
       CD4+ lymphocyte counts (< 200, 200-499, > 499/microL). When CD4+
       lymphocyte level was controlled for, women prescribed zidovudine during
       pregnancy were less likely to transmit HIV-1 to their infants (adjusted
       odds ratio, 0.36; 95% confidence interval, 0.14-0.92). There was no
       conclusive evidence that efficacy of zidovudine depended on CD4+
       lymphocyte level, suggesting that women with severe CD4+ cell
       depression, who are at highest risk of transmitting HIV-1, may also
       benefit from zidovudine. Antenatal zidovudine treatment alone may
       substantially lower the risk of perinatal HIV-1 transmission. These data
       are consistent with the results of AIDS Clinical Trial Group protocol
       076 and suggest that a substantial portion of zidovudine's protective
       effect may occur when used during the antenatal period.
 DE    Case-Control Studies  CD4-CD8 Ratio  Disease Transmission,
       Vertical/*PREVENTION & CONTROL  Drug Resistance, Microbial  Female
       Human  HIV Infections/DRUG THERAPY/IMMUNOLOGY/*PREVENTION & CONTROL/
       TRANSMISSION  HIV Seropositivity/DRUG THERAPY/TRANSMISSION  Infant,
       Newborn  *Perinatal Care  Pregnancy  Pregnancy Complications,
       Infectious/*DRUG THERAPY/VIROLOGY  Prenatal Care  Retrospective Studies
       Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.
       Zidovudine/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).